Given the immune-suppressive, hypoxic, and desmoplastic environment in CCA, targeting the IDO/TDO-AhR axis, along with metabolic and ICB, may offer new avenues for enhancing anti-tumor immunity in CCA patients. The gene discussed is IDO1; the disease is neoplasm.